Payment overview · 2025
General Payments
$11,437.29
63 reported records · 15 companies
Healthcare provider profile · identity verified
Nancy Luongo Witherspoon, DO
Allopathic & Osteopathic Physicians|Family Medicine · DANDRIDGE, TN · NPI 1760481451
Verified facts
What the public records show
CMS Open Payments records show Nancy Luongo Witherspoon, DO received $11,437.29 in general payments during 2025 across 63 reported records.
Kedplasma LLC accounted for 92.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 756 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kedplasma LLC | Unresolved — no canonical attribution shown | $10,590.00 | 92.6% | 16 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $158.48 | 1.4% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $146.20 | 1.3% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $123.35 | 1.1% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $106.77 | 0.9% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $105.26 | 0.9% | 6 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $36.59 | 0.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $35.12 | 0.3% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.97 | 0.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.17 | 0.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.93 | 0.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.51 | 0.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.99 | 0.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.00 | 0.1% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $13.95 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $10,590.00 | 16 |
| Food and Beverage | $802.29 | 46 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $128.12 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $106.77 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $78.35 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $78.35 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $71.90 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $65.86 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $65.86 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $58.07 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $52.97 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $52.11 | 3 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $36.59 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $35.12 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $34.87 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.40 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $30.36 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 756 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 28 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 80 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 89 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 112 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
112 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
756 | 94 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
80 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 814 | 204 |
| Atorvastatin Calcium | Atorvastatin Calcium | 810 | 199 |
| Eliquis | Apixaban | 756 | 94 |
| Metoprolol Tartrate | Metoprolol Tartrate | 579 | 90 |
| Sertraline Hcl | Sertraline Hcl | 540 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 528 | 129 |
| Lisinopril | Lisinopril | 519 | 142 |
| Trazodone Hcl | Trazodone Hcl | 496 | 96 |
| Buspirone Hcl | Buspirone Hcl | 456 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 454 | 121 |
| Furosemide | Furosemide | 451 | 98 |
| Losartan Potassium | Losartan Potassium | 439 | 106 |
| Divalproex Sodium | Divalproex Sodium | 413 | 44 |
| Omeprazole | Omeprazole | 382 | 101 |
| Potassium Chloride | Potassium Chloride | 364 | 80 |
| Escitalopram Oxalate | Escitalopram Oxalate | 334 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 333 | 46 |
| Alprazolam | Alprazolam | 316 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 307 | 63 |
| Montelukast Sodium | Montelukast Sodium | 300 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 295 | 65 |
| Donepezil Hcl | Donepezil Hcl | 273 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 267 | 41 |
| Allopurinol | Allopurinol | 264 | 48 |
| Mirtazapine | Mirtazapine | 251 | 55 |
| Simvastatin | Simvastatin | 228 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 218 | 60 |
| Gabapentin | Gabapentin | 218 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 213 | 64 |
| Metformin Hcl | Metformin Hcl | 204 | 58 |
| Famotidine | Famotidine | 202 | 38 |
| Carvedilol | Carvedilol | 178 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 178 | 21 |
| Meloxicam | Meloxicam | 177 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 174 | 56 |
| Clonazepam | Clonazepam | 163 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 150 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 148 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 147 | 42 |
| Glipizide Er | Glipizide | 136 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 53 |
| Tramadol Hcl | Tramadol Hcl | 135 | 31 |
| Alendronate Sodium | Alendronate Sodium | 134 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 132 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 124 | 35 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 123 | 25 |
| Midodrine Hcl | Midodrine Hcl | 120 | 13 |
| Ezetimibe | Ezetimibe | 118 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 118 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 116 | 30 |
| Glimepiride | Glimepiride | 116 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 115 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 49 |
| Mounjaro | Tirzepatide | 112 | 15 |
| Benazepril Hcl | Benazepril Hcl | 111 | 25 |
| Olanzapine | Olanzapine | 110 | 17 |
| Bumetanide | Bumetanide | 107 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 105 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 104 | 21 |
| Lorazepam | Lorazepam | 100 | 18 |
| Lovastatin | Lovastatin | 100 | 17 |
| Prednisone | Prednisone | 100 | 60 |
| Bupropion Xl | Bupropion Hcl | 95 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 94 | 25 |
| Myrbetriq | Mirabegron | 94 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 93 | 24 |
| Memantine Hcl | Memantine Hcl | 91 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 91 | 45 |
| Spironolactone | Spironolactone | 91 | 20 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 89 | 24 |
| Jardiance | Empagliflozin | 89 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 86 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 25 |
| Levetiracetam | Levetiracetam | 83 | 11 |
| Metformin Hcl Er | Metformin Hcl | 83 | suppressed |
| Baclofen | Baclofen | 82 | 14 |
| Clonidine Hcl | Clonidine Hcl | 82 | 28 |
| Januvia | Sitagliptin Phosphate | 82 | 13 |
| Linzess | Linaclotide | 81 | 18 |
| Atenolol | Atenolol | 80 | 21 |
| Gemtesa | Vibegron | 80 | suppressed |
| Nystatin | Nystatin | 76 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 25 |
| Xarelto | Rivaroxaban | 67 | 18 |
| Metolazone | Metolazone | 65 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 63 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 12 |
| Aripiprazole | Aripiprazole | 60 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 17 |
| Pregabalin | Pregabalin | 59 | 12 |
| Brilinta | Ticagrelor | 55 | suppressed |
| Azithromycin | Azithromycin | 53 | 41 |
| Trulicity | Dulaglutide | 51 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 50 | 16 |
| Glipizide | Glipizide | 50 | 14 |
| Meclizine Hcl | Meclizine Hcl | 50 | 11 |
| Methocarbamol | Methocarbamol | 50 | 21 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 50 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 49 | 14 |
| Lamotrigine | Lamotrigine | 48 | suppressed |
| Sucralfate | Sucralfate | 48 | 15 |
| Valsartan | Valsartan | 48 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 37 |
| Fluconazole | Fluconazole | 46 | 26 |
| Propranolol Hcl | Propranolol Hcl | 46 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 42 |
| Ceftriaxone | Ceftriaxone Sodium | 44 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | suppressed |
| Nifedipine Er | Nifedipine | 43 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 12 |
| Celecoxib | Celecoxib | 41 | suppressed |
| Cephalexin | Cephalexin | 41 | 30 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 28 |
| Tacrolimus | Tacrolimus | 41 | suppressed |
| Cefdinir | Cefdinir | 40 | 30 |
| Diazepam | Diazepam | 40 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 40 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 40 | 25 |
| Dapagliflozin | Dapagliflozin Propanediol | 39 | suppressed |
| Klor-Con 10 | Potassium Chloride | 39 | 11 |
| Risperidone | Risperidone | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | 12 |
| Doxepin Hcl | Doxepin Hcl | 37 | suppressed |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Gemfibrozil | Gemfibrozil | 37 | suppressed |
| Ozempic | Semaglutide | 37 | suppressed |
| Latanoprost | Latanoprost | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 36 | 12 |
| Finasteride | Finasteride | 35 | 13 |
| Sodium Chloride | 0.9 % Sodium Chloride | 35 | 21 |
| Digoxin | Digoxin | 34 | suppressed |
| Estradiol | Estradiol | 33 | 11 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | 14 |
| Temazepam | Temazepam | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 26 |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Lactulose | Lactulose | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 16 |
| Albuterol Sulfate | Albuterol Sulfate | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 15 |
| Tradjenta | Linagliptin | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | 12 |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 21 |
| Anastrozole | Anastrozole | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Budesonide | Budesonide | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | 15 |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Enulose | Lactulose | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 20 | 14 |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 18 | 16 |
| Sulfasalazine Dr | Sulfasalazine | 18 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 16 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 15 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Ertapenem | Ertapenem Sodium | 14 | suppressed |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Nexium | Esomeprazole Magnesium | 14 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Cetirizine Hcl | Cetirizine Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Ceftriaxone | Ceftriaxone In Is-Osm Dextrose | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Ziprasidone Mesylate | Ziprasidone Mesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $11,437.29 · 63 records | Kedplasma LLC | AIRSUPRA, AREXVY, Auvelity, BREZTRI, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, GEMTESA, INSPIRE, JARDIANCE, Korlym, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, WaveWriter Alpha Prime 16, Wegovy, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error